Table 7.

The clinical trials of tumor vaccine and CAR-T in TNBC

Drug name	Com	Num	Regiments	Phase	Status	Object	POM	NCT number
Neoantigen vaccine	Nab-paclitaxel plus Durvalumab	70	Vaccine and poly-ICLC SC: on days 1, 4, 8, 15, 22, 50, and 78 Nab-paclitaxel: iv on days 1, 8, and 15 of each cycle Durvalumab: iv on day 1 of each cycle	II	Recruiting	Advanced or mTNBC	PFS	NCT03606967
anti-meso CAR-T cells		20	a standard 3 + 3 dose escalation approach	I	Unknown	TNBC	AEs	NCT02580747
cMet RNA CAR T cells		6	3 × 10^7 or 3 × 10^8 cells	I	Completed	mTNBC	AEs	NCT01837602
CART-TnMUC1 cells		112	Single iv administration	I	Active, not recruiting	HER2- TNBC	DLTs	NCT04025216
EGFR/B7H3 CAR-T cells		30	2 × 10^6/kg CAR-T cells	I	Recruiting	TNBC	AEs	NCT05341492
NKG2DL-targeting CAR-grafted γδ-T Cells		10	"3 + 3" dose escalation study design ranging from 3 × 10^8—3 × 10^9 CAR-γδ-T cells. Each cycle of therapy will consist of 4 iv, given 7 days apart	I	Unknown	TNBC	DLTs	NCT04107142
ROR1-targeted CAR T cells (LYL797)		54	NA	I	Recruiting	TNBC	DLTs, TEAEs	NCT05274451
ROR1-CAR-T cell		21	ROR1 CAR-specific autologous T-lymphocytes IV over 20–30 min	I	Terminated	TNBC	AEs	NCT02706392
PD-1+ TILs		20	5 to 10 mg/mL/min	I/II	Not yet recruiting	PD1+ TNBC	AEs, PFS	NCT05451784
TC-510		115	NA	I/II	Recruiting	TNBC	DLTs, ORR	NCT05451849
BT-001	Pembrolizumab	48	BT-001: administered at different dose Pembrolizumab: 200 mg iv q3w	I/II	Recruiting	TNBC	AEs	NCT04725331

CAR-T: chimeric antigen receptor-T cell; mTNBC: metastatic triple negative breast cancer; HER2-: HER2 negative; mBC: metastatic breast cancer; gBRCA1/2 m: germline BRCA1/2 mutated; ORR: overall response rate; AEs: adverse events; PFS: progression-free survival; DLTs: dose-limiting toxicity; TEAEs: treatment emergent adverse events; ROR1: receptor tyrosine kinase like orphan receptor 1; PD-1: programmed cell death protein 1; EGFR: epidermal growth factor receptor; NKG2DL: natural killer group 2, member D